To view this email as a web page, click here

   Home

Subscribe

Advertise

 

 

 

 

January 23, 2018

Today's Rundown

Featured Story

Tmunity nabs $100M for next-gen T-cell immunotherapies

Tmunity is working to create safer and more effective T-cell therapies for solid tumors and blood cancers and is doing so in a "hybrid" manner, leveraging its relationship with the University of Pennsylvania with an eye toward expanding to its own facilities as the company matures.

Top Stories

Amgen, Novartis’ migraine drug Aimovig hits endpoints in phase 3b

With its PDUFA date approaching, Amgen and Novartis’ migraine drug has hit its primary and secondary endpoints in a study of migraine patients who have failed multiple other treatments.

ChemoCentryx eyes combinations after posting pancreatic cancer OS data 

ChemoCentryx has posted 18-month survival data from a phase 1b trial of one of its CCR2 inhibitors in pancreatic cancer patients. Almost 30% of the participants were still alive 18 months after starting treatment on a combination of CCX872 and the chemotherapy regimen FOLFIRINOX. 

New York sketches out $500M plan to build a biotech hub

New York City is doubling down on its long-discussed, never-realized dream of building a biotech hub to rival South San Francisco and Boston. The latest iteration of the dream comes backed by a $500 million financing package and a goal to quadruple the amount of R&D space in the city.

Right after Takeda deal, Denali medical director heads to rival Alkahest

Hard on the heels of a big IPO and a lucrative deal with Takeda, one of Denali’s top executives is leaving the company to join anti-aging startup Alkahest.

Disarm nabs Takeda, Pfizer executive to help neuro R&D goals

Preclinical neurological disease biotech Disarm has poached Big Pharma executive Thomas Engber, Ph.D., as its new SVP and head of neuropharmacology and translational sciences.

Merck's Keytruda makes liver-cancer headway, putting BMS and Bayer on notice

Kidney cancer isn’t the only disease where Keytruda is moving in to challenge Bristol-Myers Squibb’s Opdivo. With some new data, the Merck drug is putting liver cancer in its sights, too.

Enrollment Showcase

Online Graduate Programs Designed for Your Career

Drexel University’s online graduate programs in biomedicine, clinical research, drug discovery, and molecular medicine were developed with working professionals in mind, providing you with the education, practical skills, and competitive edge you need to be successful in your career. Learn more.

Resources

[Whitepaper] Streamline your mAb Intact Protein Characterization: Download App Note

This Agilent intact protein analysis includes:

[Marketplace] Asia-Pacific Compliance Training for Life Sciences Professionals

Don’t miss this educational program trusted by multi-national companies as part of their employee’s compliance training. Explore legal, regulatory and ethical issues faced by pharmaceutical, biotech and medical device manufacturers operating in the Asia-Pacific region. Visit event page for session topics.

[Whitepaper] Is Your In-House Strategy Ready For The Uncertainties Of Biologic Drug Development?

Download Patheon’s whitepaper to discover two main areas where a drug developer can face significant obstacles during biologics development and how by evaluating these capabilities, it can answer the critical question of whether its in-house strategy is ready for these uncertainties.

[Webinar] How to Prevent, Identify, and Implement a Clinical Trial Rescue

What do you do when timelines are missed, data is dirty, and everyone is pointing fingers? Join this webinar to learn how to prevent, identify, and implement a successful clinical trial rescue.

 

[Whitepaper] Key to regulatory transformation is unified RIM

Expanding into new markets places a spotlight on inefficient processes.

[Whitepaper] Best Practices for Managing Regulatory Processes 

Regulatory leaders share challenges and best practices from a lack of standardization, manual processes, and fragmented systems.

[Whitepaper] Choosing the Right Solution: Improving the Site Feasibility Process

Selecting the right sites to conduct your clinical trials will determine the success or failure of meeting your enrollment goals.

[Whitepaper] 5 Steps to Managing Quality Globally

Read this guide if you’re a global life sciences company - conducting clinical trials across several countries, or manufacturing and distributing products in multiple regions - to learn five steps to align and improve quality oversight, as well as avoid common mistakes in harmonization initiatives.

[Whitepaper] How Do Sponsors Ensure Quality in Global Clinical Trials?

Global clinical trials are the trend and gaining in popularity, but running a global trial is not a straightforward process. This white paper explores some of the challenges associated with global clinical trials and considerations for ensuring that the collected data comply with the trial's overall objectives.

[Webinar] Validating a 7 Day Membrane Filtration Sterility Test using Celsis®

Join us as we discuss how Charles River Celsis® helped Labor L+S AG validate a 7-day membrane filtration sterility test using existing protocols.

[Infographic] Evolution of Flexible Commercial Biologics Manufacturing

Learn how Catalent Biologics is paving the way for flexible biologics development and manufacturing through advanced technologies and fully integrated multi-product facility.

[eBook] Developing Site-specifically Modified ADCs: Using a Chemoenzymatic Approach

Download the eBook to get articles from various Elsevier journals highlighting developments in ADC technology.

[Article] Optimizing titer and use of a specific enzyme for generating a fully processed antibody

Learn how cell development and process scale-up can be optimized for antibodies requiring additional processing.

[Webinar] Within-Subject Clinical Trials: Intro to New Methods & Stat. Models

In this webinar, we will introduce the rapidly-evolving within-subject clinical trial (WSCT) methods for early phase evidence generation that require fewer people, less time, and usually less funding than traditional early phase methods.

Events

.